{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:11:22Z","timestamp":1761894682041},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1016\/j.neurol.2007.12.005","type":"journal-article","created":{"date-parts":[[2008,3,7]],"date-time":"2008-03-07T19:13:58Z","timestamp":1204917238000},"page":"233-241","source":"Crossref","is-referenced-by-count":6,"title":["Prise en charge des n\u00e9vrites optiques isol\u00e9es en France\u00a0: enqu\u00eate aupr\u00e8s des neurologues et des ophtalmologistes"],"prefix":"10.1016","volume":"164","author":[{"given":"O.","family":"Calvetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Vignal-Clermont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.D.","family":"Drews-Botsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.J.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.J.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Biousse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2007.12.005_bib1","unstructured":"Agence Nationale d\u2019Accr\u00e9ditation et d\u2019\u00c9valuation en Sant\u00e9. Conf\u00e9rence de consensus. Scl\u00e9rose en plaques. 2001, http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/sclerose3.pdf."},{"key":"10.1016\/j.neurol.2007.12.005_bib2","first-page":"45","article-title":"The natural history of optic neuritis","volume":"3","author":"Atkins","year":"2006","journal-title":"Rev Neurol Dis"},{"key":"10.1016\/j.neurol.2007.12.005_bib3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/archopht.1992.01080150029020","article-title":"The optic neuritis treatment trial. Implications for clinical practice","volume":"110","author":"Beck","year":"1992","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.neurol.2007.12.005_bib4","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis","volume":"326","author":"Beck","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2007.12.005_bib5","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/archopht.1993.01090060061023","article-title":"Optic neuritis treatment trial. One-year follow-up results","volume":"111","author":"Beck","year":"1993","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.neurol.2007.12.005_bib6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ana.10148","article-title":"Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses","volume":"51","author":"Beck","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2007.12.005_bib7","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/archopht.121.7.944","article-title":"High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial","volume":"121","author":"Beck","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.neurol.2007.12.005_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0002-9394(03)00862-6","article-title":"Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial","volume":"137","author":"Beck","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.neurol.2007.12.005_bib9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s004150070172","article-title":"Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials","volume":"247","author":"Brusaferri","year":"2000","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2007.12.005_bib10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0002-9394(01)01209-0","article-title":"Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis","volume":"132","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.neurol.2007.12.005_bib11","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1212\/WNL.51.3.885","article-title":"The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis","volume":"51","author":"Cole","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2007.12.005_bib12","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(00)04725-5","article-title":"Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study","volume":"357","author":"Comi","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2007.12.005_bib13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ana.10240","article-title":"Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis","volume":"52","author":"Dalton","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2007.12.005_bib14","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ana.10580","article-title":"New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes","volume":"53","author":"Dalton","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2007.12.005_bib15","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0035-3787(07)90472-5","article-title":"Donn\u00e9es \u00e9pid\u00e9miologiques et analyse de l\u2019offre de soins de la scl\u00e9rose en plaques en France","volume":"163","author":"Debouverie","year":"2007","journal-title":"Rev Neurol (Paris)"},{"journal-title":"Ophthalmology","article-title":"Visual function 15 years afetr Optic Neuritis a final follow-up report from the Optic Neuritis treatment trial","year":"2007","key":"10.1016\/j.neurol.2007.12.005_bib16"},{"key":"10.1016\/j.neurol.2007.12.005_bib17","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1212\/01.WNL.0000082654.99838.EF","article-title":"The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"61","author":"Frohman","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2007.12.005_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1474-4422(05)00992-0","article-title":"The neuro-ophthalmology of multiple sclerosis","volume":"4","author":"Frohman","year":"2005","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2007.12.005_bib19","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1001\/archneur.63.4.614","article-title":"Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis","volume":"63","author":"Frohman","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2007.12.005_bib20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/jnnp.72.1.119","article-title":"Evaluation of the management of optic neuritis: audit on the neurological and ophthalmological practice in the north west of England","volume":"72","author":"Ghosh","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2007.12.005_bib21","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Commission de transparence. Avonex. 2002, http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/ct031305.pdf."},{"key":"10.1016\/j.neurol.2007.12.005_bib22","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Commission de la transparence. Betaferon. 2006, http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/ct-3083_betaferon.pdf."},{"key":"10.1016\/j.neurol.2007.12.005_bib23","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Guide Affection de longue dur\u00e9e\u00a0: la scl\u00e9rose en plaques. Septembre 2006, http:\/\/www.has-sante.fr."},{"key":"10.1016\/j.neurol.2007.12.005_bib24","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Guide M\u00e9thodologique\u00a0: M\u00e9thode et processus d\u2019adaptation des recommandations pour la pratique clinique existantes. F\u00e9vrier 2007, http:\/\/www.has-sante.fr."},{"key":"10.1016\/j.neurol.2007.12.005_bib25","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Guide M\u00e9thodologique\u00a0: \u00c9laboration de crit\u00e8res de qualit\u00e9 pour l\u2019\u00e9valuation et l\u2019am\u00e9lioration des pratiques professionnelles. Mai 2007, http:\/\/www.has-sante.fr."},{"key":"10.1016\/j.neurol.2007.12.005_bib26","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(02)11919-2","article-title":"Management of acute optic neuritis","volume":"360","author":"Hickman","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2007.12.005_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijmedinf.2003.09.002","article-title":"An investigation into low mail survey response rates of information technology users in health care organizations","volume":"72","author":"Hikmet","year":"2003","journal-title":"Int J Med Inform"},{"key":"10.1016\/j.neurol.2007.12.005_bib28","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM200009283431301","article-title":"Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis","volume":"343","author":"Jacobs","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2007.12.005_bib29","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1212\/01.wnl.0000237641.33768.8d","article-title":"Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes","volume":"67","author":"Kappos","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2007.12.005_bib30","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(07)61194-5","article-title":"Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study","volume":"370","author":"Kappos","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2007.12.005_bib31","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1212\/WNL.54.11.2039","article-title":"Practice parameter: the role of corticosteroids in the management of acute monosymtomatic optic neuritis. Report of the Quality Standards Subcommittee of the American of Neurology","volume":"54","author":"Kaufman","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2007.12.005_bib32","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/01.wnl.0000200778.65597.ae","article-title":"IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event","volume":"66","author":"Kinkel","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2007.12.005_bib33","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1474-4422(06)70353-2","article-title":"MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study","volume":"5","author":"Korteweg","year":"2006","journal-title":"Lancet Neurol"},{"issue":"Suppl. 4","key":"10.1016\/j.neurol.2007.12.005_bib34","first-page":"IV30","article-title":"The pros and cons of early treatment of relapsing forms of multiple sclerosis","volume":"25","author":"Montalban","year":"2004","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2007.12.005_bib35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2288-6-5","article-title":"Maximising response to postal questionnaires - a systematic review of randomised trials in health research","volume":"6","author":"Nakash","year":"2006","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.neurol.2007.12.005_bib36","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/archneur.63.4.611","article-title":"Not every patient with multiple sclerosis should be treated at time of diagnosis","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2007.12.005_bib37","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria\u201d","volume":"58","author":"Polman","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2007.12.005_bib38","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1212\/01.wnl.0000184493.06254.a6","article-title":"Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution","volume":"65","author":"Rovaris","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2007.12.005_bib39","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1445-5994.2000.tb00832.x","article-title":"The use of evidence-based medicine in the practice of consultant physicians. Results of a questionnaire survey","volume":"30","author":"Scott","year":"2000","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.neurol.2007.12.005_bib40","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1212\/WNL.52.7.1479","article-title":"A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis","volume":"52","author":"Sellebjerg","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2007.12.005_bib41","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S1474-4422(07)70176-X","article-title":"MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study","volume":"6","author":"Swanton","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2007.12.005_bib42","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0161-6420(99)90482-7","article-title":"The impact of the optic neuritis treatment trial on the practices of ophthalmologists and neurologists","volume":"106","author":"Trobe","year":"1999","journal-title":"Ophthalmology"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378708000441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378708000441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T06:20:16Z","timestamp":1546237216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378708000441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0035378708000441"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2007.12.005","relation":{},"ISSN":["0035-3787"],"issn-type":[{"type":"print","value":"0035-3787"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}